Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment
- 30 September 2025
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (4) , 474-486
Abstract
Objective: Dopamine agonists and somatostatin analogs are commonly used in prolactinomas and somatotropinomas. Response to these therapies is heterogeneous. Whether resistance is linked to specific tumor subtypes or to shared mechanisms of resistance is not known. The aim was to explore distinct molecular subtypes of prolactinomas and somatotropinomas and their association with response to treatment. Methods: The transcriptome of 46 prolactinomas and 58 somatotropinomas was analyzed. Unsupervised classifications were generated and tested for association with histological and clinical data, including response to treatment. Results: Four subtypes of prolactinomas were identified, with variable sensitivity to dopamine agonists (P < 10−4). Sensitive tumors accumulated in the subgroup with the highest DRD2 expression, while resistant tumors accumulated in the 3 remaining ones, enriched in genes related to cAMP metabolism, to mitochondrial and ribosomal activity, and to immunity, respectively. Sparsely granulated somatotropinomas (N = 16) presented a separated molecular entity, mixing tumors resistant and sensitive to somatostatin analogs. The remaining somatotropinomas were classified into 5 subtypes, with variable sensitivity to somatostatin analogs (P < 10−4). Sensitive tumors accumulated in 3 subgroups, characterized by GNAS somatic mutation, PIT1 and SF1 coexpression, and the stem-cell marker SOX2 expression, respectively. Resistant tumors accumulated in the 2 remaining ones, enriched in genes related to cell cycle and to mesenchymal differentiation, respectively. Somatostatin receptor 2 (SSTR2) expression was associated with response to somatostatin analogs in sparsely granulated somatotropinomas (P = .022), but not in other somatotropinomas (P = .923). Conclusions: Prolactinomas and somatotropinomas were classified into distinct transcriptomic groups. Resistance to medical therapies was linked to distinct tumor subtypes, suggesting distinct mechanisms of resistance.Keywords
Funding Information
- La Fondation Foch
- SIRIC CARPEM
This publication has 81 references indexed in Scilit:
- Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular featuresActa Neuropathologica, 2024
- The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatmentActa Neuropathologica, 2020
- A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposalVirchows Archiv, 2019
- Diagnosis and Treatment of Pituitary AdenomasJAMA, 2017
- Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experiencePituitary, 2012
- Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegalyInternational Journal of Cancer, 2009
- Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatmentPituitary, 2009
- Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinomaPituitary, 2009
- Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remissionPituitary, 2007
- Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotideJournal of Endocrinological Investigation, 1999